AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9827783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ardeparin and Unfractionated heparin
Number of subjects: 80
Study 7712665 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (20 minutes)
Number of subjects: 10
Study 7712665 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake (standardized meal)
Number of subjects: 10
Study 7712665 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 10
Study 2970788 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 29
Study 2970788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29209778 — intervention group
Group type: EXPERIMENTAL
Intervention: Prourokinase injection (20 mg intravenously followed by 30 mg intravenous infusion within 30 min)
Number of subjects: 1851
Study 29209778 — intervention group
Group type: EXPERIMENTAL
Intervention: Prourokinase injection
Number of subjects: 1851
Study 27655440 — intervention group
Group type: COMPARATOR
Intervention: leucine-10g
Number of subjects: 12
Study 27655440 — intervention group
Group type: COMPARATOR
Intervention: leucine-5g
Number of subjects: 12
Study 27655440 — intervention group
Group type: COMPARATOR
Intervention: isoleucine-10g
Number of subjects: 12
Study 27655440 — intervention group
Group type: COMPARATOR
Intervention: isoleucine-5g
Number of subjects: 12
Study 25129820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 270
Study 25129820 — intervention group
Group type: COMPARATOR
Intervention: Control (no intravenous metoprolol)
Number of subjects: 270
Study 23514019 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention detailing risks and safe alternatives to benzodiazepines
Number of subjects: 250
Study 23514019 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 250
Study 23514019 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 250
Study 21540395 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 285
Study 21540395 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine co‐formulated (AAcf)
Number of subjects: 285
Study 21540395 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine co‐packaged (AAcp)
Number of subjects: 285
Study 19399951 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet
Number of subjects: 1209
Study 16720082 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based incentives delivered contingent on biochemically-verified abstinence
Number of subjects: 129
Study 16720082 — intervention group
Group type: COMPARATOR
Intervention: Control condition wherein incentives were given independent of smoking status
Number of subjects: 129
Study 15476300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of fetal biparietal diameter (BPD)
Number of subjects: 122
Study 15476300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of abdominal circumference (AC)
Number of subjects: 122
Study 15476300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of head circumference (HC)
Number of subjects: 122
Study 15476300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver measurements of femur length (FL)
Number of subjects: 122
Study 15476300 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver measurements of fetal biparietal diameter (BPD)
Number of subjects: 122
Study 15476300 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver measurements of abdominal circumference (AC)
Number of subjects: 122
Study 15476300 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver measurements of head circumference (HC)
Number of subjects: 122
Study 15476300 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver measurements of femur length (FL)
Number of subjects: 122
Study 11758232 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS 844ins68
Number of subjects: 275
Study 11758232 — intervention group
Group type: EXPERIMENTAL
Intervention: MS A2756G
Number of subjects: 275
Study 11758232 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T
Number of subjects: 275
Study 11758232 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 275
Study 9154893 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled leukotriene B4 (17.6 +/- 3.4 microg for normal subjects; 18.2 +/- 1.9 microg for asthmatics)
Number of subjects: 12
Study 9154893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7966812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerated limbs (CVI class 3)
Number of subjects: 120
Study 7966812 — intervention group
Group type: COMPARATOR
Intervention: Contralateral 'normal' limbs (CVI class 0)
Number of subjects: 120
Study 4074450 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg proglumetacin t.i.d.
Number of subjects: 0
Study 4074450 — intervention group
Group type: COMPARATOR
Intervention: 50 mg indometacin t.i.d.
Number of subjects: 0
Study 31945149 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD)
Number of subjects: 1334
Study 31945149 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
Number of subjects: 1334
Study 31945149 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD) in PET2- patients aged <60 years
Number of subjects: 1334
Study 31945149 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in PET2- patients aged <60 years
Number of subjects: 1334
Study 31945149 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD) in PET2+ patients aged <60 years
Number of subjects: 1334
Study 31945149 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in PET2+ patients aged <60 years
Number of subjects: 1334
Study 29452985 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural hygiene training and kinesiotherapy for 12 weeks, 2 days a week, 1 hour per session
Number of subjects: 33
Study 29452985 — intervention group
Group type: EXPERIMENTAL
Intervention: Home adaptation
Number of subjects: 33
Study 29452985 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 26954273 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-selected nonthrust manipulation
Number of subjects: 63
Study 26954273 — intervention group
Group type: COMPARATOR
Intervention: Prescriptively selected nonthrust manipulation
Number of subjects: 63
Study 24635880 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly monitoring
Number of subjects: 2215
Study 24635880 — intervention group
Group type: COMPARATOR
Intervention: 6-monthly monitoring
Number of subjects: 2215
Study 24635880 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness of 6-monthly monitoring
Number of subjects: 2215
Study 22076708 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA4: A49G [rs231775]
Number of subjects: 531
Study 22076708 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC1: Arg339Gln [rs25487]
Number of subjects: 531
Study 22076708 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC2: Lys751Gln [rs13181]
Number of subjects: 531
Study 22076708 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53: Arg72Pro [rs1042522]
Number of subjects: 531
Study 22128444 — intervention group
Group type: EXPERIMENTAL
Intervention: Stryker Disc Dekompressor for aspiration of disc material (Group 1)
Number of subjects: 50
Study 22128444 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroid/local anesthetic injection (Group 2)
Number of subjects: 50
Study 17927726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular route (Group 1): ketamine (6 mg/kg), midazolam (0.05 mg/kg), atropine (0.02 mg/kg)
Number of subjects: 60
Study 17927726 — intervention group
Group type: COMPARATOR
Intervention: Oral route (Group 2): ketamine (10 mg/kg), midazolam (0.2 mg/kg), atropine (0.05 mg/kg)
Number of subjects: 60
Study 17477927 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II POP with prior surgery
Number of subjects: 314
Study 17477927 — intervention group
Group type: COMPARATOR
Intervention: More advanced POP
Number of subjects: 314
Study 15289374 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg gadopentetate dimeglumine
Number of subjects: 99
Study 15289374 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mmol/kg gadopentetate dimeglumine
Number of subjects: 99
Study 15289374 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mmol/kg gadopentetate dimeglumine
Number of subjects: 99
Study 11728258 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (plus indapamide)
Number of subjects: 6105
Study 11728258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 15321310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg
Number of subjects: 116
Study 15321310 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 100 microg
Number of subjects: 116
Study 15321310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg and Morphine 100 microg
Number of subjects: 116
Study 15321310 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 116
Study 1403591 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 0
Study 1403591 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxyborate rinse
Number of subjects: 0
Study 1403591 — intervention group
Group type: COMPARATOR
Intervention: Saline rinse
Number of subjects: 0
Study 1403591 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste slurry rinse
Number of subjects: 0
Study 1403591 — intervention group
Group type: COMPARATOR
Intervention: Cetylpyridinium chloride rinse
Number of subjects: 0
Study 1403591 — intervention group
Group type: COMPARATOR
Intervention: Prebrushing detergent rinse
Number of subjects: 0
Study 3894200 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal variceal sclerotherapy
Number of subjects: 120
Study 3894200 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 31599468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Multiple Assignment Randomized Trial (SMART) design
Number of subjects: 0
Study 31599468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials
Number of subjects: 0
Study 31599468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic nursing trials using SMART designs
Number of subjects: 0
Study 28686959 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated bed bath scenario
Number of subjects: 58
Study 28686959 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional teaching)
Number of subjects: 58
Study 26518090 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 727
Study 26518090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study 26518090 — intervention group
Group type: COMPARATOR
Intervention: ICS boost
Number of subjects: 727
Study 23509932 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (MI) and anticipatory guidance (AG) approaches
Number of subjects: 0
Study 23509932 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (standard early oral health screening program; 'lift the lip')
Number of subjects: 0
Study 21786489 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of normal saline
Number of subjects: 0
Study 21786489 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe push method of normal saline
Number of subjects: 0
Study 19078947 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel alpha2delta ligands (lead compound at approximately 30 mg)
Number of subjects: 0
Study 19078947 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel alpha2delta ligands (backup compound at >600 mg)
Number of subjects: 0
Study 16877536 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of body mass index (BMI)
Number of subjects: 28983
Study 16877536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster of three IRS-related conditions (hypertension, BMI >/=25 kg/m(2), HDL cholesterol <40 mg/dl)
Number of subjects: 28983
Study 14503055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoxin Recipe (TXR)
Number of subjects: 60
Study 14503055 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Recipe (BSR)
Number of subjects: 60
Study 14503055 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (Dp)
Number of subjects: 60
Study 10851645 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 million U extencilline
Number of subjects: 33
Study 10851645 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 million U extencilline
Number of subjects: 33
Study 10851645 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 million U bicillin-5
Number of subjects: 33
Study 9088591 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril
Number of subjects: 7
Study 9088591 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril/Captopril
Number of subjects: 7
Study 9088591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8256735 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided approach
Number of subjects: 21
Study 8256735 — intervention group
Group type: COMPARATOR
Intervention: Right-sided approach
Number of subjects: 21
Study 3895921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 704
Study 3895921 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole or Tobramycin plus Ticarcillin
Number of subjects: 704
Study 3895921 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin and Ticarcillin
Number of subjects: 704
Study 29860917 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy
Number of subjects: 6711
Study 29860917 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 6711
Study 29860917 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 6711
Study 26280319 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 24
Study 25208569 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based modality
Number of subjects: 253
Study 25208569 — intervention group
Group type: COMPARATOR
Intervention: Manual-based modality
Number of subjects: 253
Study 22261295 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 90
Study 22261295 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 90
Study 20417659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis with high δ9-THC contents (up to 69.4mg THC)
Number of subjects: 24
Study 17609247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (5 mg daily)
Number of subjects: 96
Study 17609247 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (0.03 mg progestogen-only pill)
Number of subjects: 96
Study 17609247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (5 mg daily) with condoms
Number of subjects: 96
Study 16216596 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet rich in fruits, vegetables and low-fat dairy products, reduced in fat (27%), saturated fat (7%), and cholesterol (150 mg/day) for 3 months
Number of subjects: 103
Study 16216596 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 103
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish patients with ischaemic stroke
Number of subjects: 17370
Study 12220692 — intervention group
Group type: COMPARATOR
Intervention: Other IST countries patients with ischaemic stroke
Number of subjects: 17370
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish patients with coronary heart disease
Number of subjects: 17370
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish patients with pulmonary embolism
Number of subjects: 17370
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish patients younger than 75 years
Number of subjects: 17370
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish female patients
Number of subjects: 17370
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish patients alert at onset
Number of subjects: 17370
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish patients with partial anterior circulation syndrome (PACS)
Number of subjects: 17370
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish patients with lacunar syndrome (LACS)
Number of subjects: 17370
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish patients without atrial fibrillation (AF)
Number of subjects: 17370
Study 12220692 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish patients on aspirin before stroke
Number of subjects: 17370
Study 9686700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro (Group I, n = 15)
Number of subjects: 69
Study 9686700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro (Group II, n = 18)
Number of subjects: 69
Study 9686700 — intervention group
Group type: COMPARATOR
Intervention: Soluble (Group III, n = 12)
Number of subjects: 69
Study 9686700 — intervention group
Group type: COMPARATOR
Intervention: Soluble injected at mealtimes (Group IV, n = 24)
Number of subjects: 69
Study 8120559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron plus dexamethasone
Number of subjects: 275
Study 8120559 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron alone
Number of subjects: 275
Study 2638180 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/PVM/MA copolymer/NaF dentifrice
Number of subjects: 0
Study 2638180 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study 1136689 — intervention group
Group type: EXPERIMENTAL
Intervention: Decelerating flow
Number of subjects: 8
Study 1136689 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant flow
Number of subjects: 8
Study 1136689 — intervention group
Group type: COMPARATOR
Intervention: Accelerating flow
Number of subjects: 8
Study 1136689 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas exchange studies (all flow patterns)
Number of subjects: 8
Study 29768292 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared vein visualization device support
Number of subjects: 54
Study 31290715 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugated vaccine (PCV13)
Number of subjects: 136
Study 31290715 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 136
Study 31290715 — intervention group
Group type: COMPARATOR
Intervention: Both vaccines (PPV23 and PCV13)
Number of subjects: 136
Study 29032957 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive-day dosing of 60 mg iron at 0800 h for 14 days
Number of subjects: 60
Study 29032957 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day dosing of 60 mg iron at 0800 h for 28 days
Number of subjects: 60
Study 29032957 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 120 mg iron at 0800 h for 3 days
Number of subjects: 60
Study 29032957 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily divided dosing of 60 mg iron at 0800 h and 1700 h for 3 days
Number of subjects: 60
Study 24385202 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNFα therapy (infliximab and etanercept)
Number of subjects: 0
Study 24070742 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐via‐CALC
Number of subjects: 45
Study 24070742 — intervention group
Group type: COMPARATOR
Intervention: LEARN Program
Number of subjects: 45
Study 21469401 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical (papain‐based gel followed by curette)
Number of subjects: 84
Study 21469401 — intervention group
Group type: COMPARATOR
Intervention: Mechanical (curette‐‐control group)
Number of subjects: 84
Study 21469401 — intervention group
Group type: EXPERIMENTAL
Intervention: SB (Adper Single Bond 2)
Number of subjects: 84
Study 21469401 — intervention group
Group type: EXPERIMENTAL
Intervention: SE (Clearfil SE Bond)
Number of subjects: 84
Study 21469401 — intervention group
Group type: EXPERIMENTAL
Intervention: TriS (Clearfil Tri‐S Bond)
Number of subjects: 84
Study 19737848 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic stenting (ERCP with sphincterotomy and PD stenting)
Number of subjects: 0
Study 19737848 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 19737848 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic stenting
Number of subjects: 0
Study 17013572 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT with electrons at 20 Gy
Number of subjects: 47
Study 17013572 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT with electrons at 22 Gy
Number of subjects: 47
Study 17013572 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT with electrons at 24 Gy
Number of subjects: 47
Study 17013572 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT with electrons
Number of subjects: 47
Study 15556056 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 3034
Study 15556056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3034
Study 10998741 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic only
Number of subjects: 180
Study 10998741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarapin added to local anesthetic
Number of subjects: 180
Study 10998741 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medrol along with Sarapin
Number of subjects: 180
Study 9625848 — intervention group
Group type: EXPERIMENTAL
Intervention: LDLR positive (LDLR+)
Number of subjects: 90
Study 9625848 — intervention group
Group type: COMPARATOR
Intervention: LDLR negative (LDLR-)
Number of subjects: 90
Study 9625848 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of LDLR
Number of subjects: 90
Study 7877082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpedicle connective tissue graft
Number of subjects: 15